Gilles Salles

115PUBLICATIONS
610CO-AUTHORS
Haematological tumoursGene expression (incl. microarray and other genome-wide approaches)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (115)

|Oct 02, 2026
Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial.

|Sep 09, 2026
LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma.

|Aug 31, 2026
Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma.

|Jul 10, 2026
Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma.

|Jun 30, 2026
Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs.

|Jun 09, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Pageof 20

Frequent Collaborators

21 joint publications

Ahmet Dogan

19 joint publications

Maria Lia Palomba

19 joint publications

Andrew D Zelenetz

18 joint publications

Miguel-Angel Perales